Patents Assigned to Bioverativ Therapeutics Inc.
-
Publication number: 20230338344Abstract: This disclosure to methods for treating or preventing particular symptoms and disorders which are associated with blood disorders using AMPK activators. Also disclosed are pharmaceutical composition comprising an AMPK activator for use in said methods.Type: ApplicationFiled: March 28, 2023Publication date: October 26, 2023Applicant: Bioverativ Therapeutics Inc.Inventors: Pauline RIMMELÉ, Dieter SCHMOLL, Yannis HARA
-
Patent number: 11787851Abstract: The present invention provides codon optimized Factor VIII sequences, vectors and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides. The present invention also provides methods of treating bleeding disorders such as hemophilia comprising administering to the subject a codon optimized Factor VIII nucleic acid sequence or the polypeptide encoded thereby.Type: GrantFiled: June 25, 2019Date of Patent: October 17, 2023Assignee: BIOVERATIV THERAPEUTICS INC.Inventors: Siyuan Tan, Robert T. Peters
-
Patent number: 11753461Abstract: The present disclosure provides codon optimized Factor VIII sequences, vectors, and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides. The present disclosure also provides methods of treating bleeding disorders such as hemophilia comprising administering to the subject a codon optimized Factor VIII nucleic acid sequence or the polypeptide encoded thereby.Type: GrantFiled: January 31, 2017Date of Patent: September 12, 2023Assignee: BIOVERATIV THERAPEUTICS INC.Inventors: Siyuan Tan, Tongyao Liu
-
Patent number: 11747351Abstract: The present invention provides methods of dosing Factor VIII or Factor IX chimeric and hybrid polypeptides. The present invention further provides high-sensitivity methods of quantifying an amount of activated FIX protein in a test sample.Type: GrantFiled: April 14, 2020Date of Patent: September 5, 2023Assignee: BIOVERATIV THERAPEUTICS INC.Inventors: Jurg Sommer, Haiyan Jiang, Xin Zhang, Buyue Yang, Glenn Pierce
-
Patent number: 11685771Abstract: Provided are recombinant Factor VIII proteins, e.g., human Factor VIII proteins with heterologous moieties inserted into flexible permissive loops located in the Factor VIII A domains, while retaining the procoagulant activity of Factor VIII.Type: GrantFiled: July 19, 2019Date of Patent: June 27, 2023Assignee: BIOVERATIV THERAPEUTICS INC.Inventor: John Kulman
-
Patent number: 11642398Abstract: The present invention provides formulations comprising a Factor IX-FcRn Binding Partner (FIXFBP) polypeptide, and methods of administering FIXFBP.Type: GrantFiled: January 27, 2020Date of Patent: May 9, 2023Assignee: BIOVERATIV THERAPEUTICS INC.Inventor: Mark Brader
-
Patent number: 11578098Abstract: The present invention is directed to a method of inactivating virus that is present during production of a polypeptide of interest. In particular, the present invention is directed to a method of on-column virus inactivation using a low pH and high salt wash solution that effectively inactivates viruses with minimum recovery loss of the polypeptide.Type: GrantFiled: February 18, 2020Date of Patent: February 14, 2023Assignee: BIOVERATIV THERAPEUTICS INC.Inventors: Glen Bolton, Keith Selvitelli
-
Patent number: 11401322Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: March 21, 2017Date of Patent: August 2, 2022Assignee: Bioverativ Therapeutics Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
-
Patent number: 11382831Abstract: Device containers, such as therapeutic kit containers, are disclosed. In one embodiment, a device container comprises a first member configured to releasably hold a syringe barrel, a second member configured to releasably hold a vial, wherein the second member is coupled to the first member by a first hinge, and a third member configured to releasably hold a vial adapter, wherein the third member is coupled to the second member by a second hinge.Type: GrantFiled: October 22, 2020Date of Patent: July 12, 2022Assignee: BIOVERATIV THERAPEUTICS INC.Inventors: Christine P. Janson, Ethan B. Jacoby, Frederick Carel Steinmann, Nikhil Gandhi, Chad Presher
-
Patent number: 11370827Abstract: The present invention provides a VWF fragment comprising the D? domain and D3 domain of VWF, a chimeric protein comprising the VWF fragment and a heterologous moiety, or a chimeric protein comprising the VWF fragment and a FVIII protein and methods of using the same. A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein. By preventing or inhibiting binding of endogenous VWF to the FVIII, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.Type: GrantFiled: January 12, 2013Date of Patent: June 28, 2022Assignee: BIOVERATIV THERAPEUTICS INC.Inventors: Ekta Seth Chhabra, Tongyao Liu, Robert T Peters, Haiyan Jiang
-
Patent number: 11372008Abstract: The present disclosure provides methods and compositions for diagnosing and treating subject having a bleeding disorder. The disclosed methods comprise contacting a sample, e.g., a blood or plasma sample obtained from the patient, with an activation mixture comprising an activated coagulation factor and a phospholipid mixture, wherein the activation mixture is dried onto a solid substrate. Also provided is a global hemostasis test based on the integration of clotting time (Ct) and pharmacokinetics data. The methods and compositions presented can be applied to point-of-care diagnostic systems.Type: GrantFiled: May 14, 2018Date of Patent: June 28, 2022Assignee: Bioverativ Therapeutics Inc.Inventor: Jurg Sommer
-
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
Patent number: 11286528Abstract: The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.Type: GrantFiled: January 11, 2019Date of Patent: March 29, 2022Assignees: BIOVERATIV THERAPEUTICS INC., PUGET SOUND BLOOD CENTERInventors: Haiyan Jiang, Tongyao Liu, Sriram Krishnamoorthy, Neil Josephson, Glenn Pierce -
Patent number: 11266720Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.Type: GrantFiled: February 7, 2019Date of Patent: March 8, 2022Assignee: BIOVERATIV THERAPEUTICS INC.Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
-
Patent number: 11261437Abstract: The present disclosure provides protease-activatable procoagulant compounds comprising a procoagulant polypeptide, e.g., a procoagulant peptide and/or clotting factor, and a linker comprising a protease-cleavable substrate (e.g., a synthetic thrombin substrate) and a self-immolative spacer (e.g., p-amino benzyl carbamate). Upon cleavage of the protease-cleavable substrate by a protease (e.g., thrombin), the self-immolative spacer cleaves itself from the procoagulant polypeptide such that the polypeptide is in an underivatized and active form. Also provided are pharmaceutical compositions, methods for treating bleeding disorders using the disclosed compounds, methods of enhancing in vivo efficacy of procoagulant polypeptides, methods of increasing the efficacy of proteolytic cleavage of compounds comprising procoagulant polypeptides, methods of activating procoagulant polypeptides, and methods of releasing a procoagulant polypeptide from a heterologous moiety such as PEG.Type: GrantFiled: March 18, 2019Date of Patent: March 1, 2022Assignee: BIOVERATIV THERAPEUTICS INC.Inventors: Vu Phong Hong, Adam R. Mezo, Joe Salas, Robert Peters
-
Patent number: 11225650Abstract: The present invention provides methods of administering long-acting Factor IX; methods of administering long-acting, chimeric and hybrid polypeptides comprising Factor IX; and methods of producing such chimeric and hybrid polypeptides using cells.Type: GrantFiled: June 9, 2017Date of Patent: January 18, 2022Assignee: Bioverativ Therapeutics Inc.Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang, Mark Brader
-
Patent number: 11193116Abstract: The present invention provides methods of administering long-acting Factor IX; methods of administering long-acting, chimeric and hybrid polypeptides comprising Factor IX; and methods of producing such chimeric and hybrid polypeptides using cells.Type: GrantFiled: June 9, 2017Date of Patent: December 7, 2021Assignee: Bioverativ Therapeutics Inc.Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang, Mark Brader
-
Patent number: 11192936Abstract: The present invention provides a chimeric protein comprising a first polypeptide which comprises a FVIII protein and a first Ig constant region or a portion thereof and a second polypeptide which comprises a VWF protein comprising the D? domain and D3 domain of VWF, a XTEN sequence having less than 288 amino acids in length, and a second Ig constant region or a portion thereof, wherein the first polypeptide and the second polypeptide are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.Type: GrantFiled: January 9, 2015Date of Patent: December 7, 2021Assignee: Bioverativ Therapeutics Inc.Inventors: Ekta Seth Chhabra, Tongyao Liu, Robert T. Peters, John Kulman
-
Patent number: 11168125Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: July 22, 2019Date of Patent: November 9, 2021Assignee: BIOVERATIV THERAPEUTICS INC.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
-
Patent number: 11168316Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.Type: GrantFiled: December 20, 2018Date of Patent: November 9, 2021Assignee: Bioverativ Therapeutics, Inc.Inventors: Joe Salas, Elena Kistanova, Vu Phong Hong, Adam R. Mezo, Robert T. Peters
-
Patent number: 11091534Abstract: The present invention provides a chimeric protein comprising a VWF protein comprising the D? domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein linked to an XTEN sequence and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to the FVIII protein, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the chimeric protein comprising a FVIII protein.Type: GrantFiled: October 8, 2018Date of Patent: August 17, 2021Assignee: Bioverativ Therapeutics Inc.Inventors: Ekta Seth Chhabra, Tongyao Liu, Pei-yun Chang, Robert T. Peters, John Kulman, Haiyan Jiang